--- title: "Why Lilly's Weight Loss Pill Isn't a Peptide" description: "Oral semaglutide destroys 99% of its active ingredient per dose. Lilly's Foundayo skips the problem entirely. Inside the $70B oral GLP-1 pill race." date: 2026-04-09 author: "Philipp D. Dubach" categories: - "Medicine" keywords: - "Foundayo vs oral Wegovy" - "orforglipron vs oral semaglutide" - "oral GLP-1 weight loss pill 2026" - "oral semaglutide bioavailability SNAC" - "GLP-1 market size obesity 2030" - "Foundayo orforglipron FDA approval 2026" - "Foundayo weight loss pill price" - "Novo Nordisk vs Eli Lilly GLP-1 2026" - "oral weight loss pill GLP-1" - "small molecule GLP-1 receptor agonist" - "oral semaglutide Wegovy pill 25mg" - "GLP-1 manufacturing cost COGS" - "semaglutide patent expiry 2031 biosimilar" - "oral GLP-1 pipeline aleniglipron VK2735 amycretin" - "GLP-1 adherence persistence discontinuation" - "anti-obesity medication market expansion" - "Jevons Paradox statin analogy GLP-1" type: "Analysis" canonical_url: "https://philippdubach.com/posts/why-lillys-weight-loss-pill-isnt-a-peptide/" source_url: "https://philippdubach.com/posts/why-lillys-weight-loss-pill-isnt-a-peptide/index.md" --- # Why Lilly's Weight Loss Pill Isn't a Peptide *Philipp D. Dubach ยท Published April 9, 2026* ## Key Takeaways - Oral semaglutide has reported bioavailability of roughly 0.4 to 1% per the EMA assessment report, meaning each pill discards most of its active ingredient before absorption - Eli Lilly's Foundayo (orforglipron) is a small molecule, not a peptide, sidestepping the oral peptide delivery problem that took the field over a century to address - Combined Novo Nordisk and Eli Lilly GLP-1 revenue hit roughly $70B in 2025; the statin precedent (197% user growth after atorvastatin went generic) suggests oral pills may expand rather than cannibalise total volume - GLP-1 penetration is under 5% of eligible US adults vs. 35%+ for statins, implying substantial room for market expansion --- ![Editorial cover illustration for an analysis of Eli Lilly's Foundayo and the oral GLP-1 weight loss pill race against Novo Nordisk's oral Wegovy](https://static.philippdubach.com/cdn-cgi/image/width=1600,quality=85,format=auto/pill-cover.jpg) >Novo Nordisk spent decades and $1.8 billion learning how to get a peptide past the gut. Eli Lilly looked at the same problem and decided to skip it entirely. Your gastrointestinal tract is a 30-foot disassembly line for proteins. Acid denatures them, pepsin cleaves them, trypsin finishes the job, and the mucus layer blocks whatever survives. Sean Geiger's excellent [history of oral peptides](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) traces the full arc: the first attempt at oral insulin was in 1922. Over a hundred years and thirteen companies later, no oral insulin exists. Novo Nordisk spent decades and $1.8 billion acquiring the technology to get around this problem. The result, approved in December 2025 as [oral Wegovy for obesity](https://www.endocrinologyadvisor.com/news/fda-approves-oral-wegovy-for-weight-management/), is a pill that destroys 99% of its own active ingredient before the remaining fraction reaches the bloodstream. The oral 25mg daily dose uses roughly 280x more semaglutide than the equivalent weekly injection. This is the best that peptide oral delivery can do. Eli Lilly decided to skip it entirely, building Foundayo, a small molecule oral obesity drug that isn't a peptide at all. That divergence in approach will determine who captures the majority of a market that [Goldman Sachs projects](https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market) at $100+ billion by 2030 and that [J.P. Morgan estimates](https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs) will reach 30 million US users within five years. ## Oral semaglutide Sean Geiger's [history of oral peptides](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) traces the science well. The technology that makes oral semaglutide possible is SNAC (salcaprozate sodium), a permeation enhancer developed by Emisphere Technologies starting in the 1990s. Novo partnered with Emisphere in 2007 and [acquired the company outright in 2020](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472). SNAC does three things simultaneously: it buffers local stomach pH to suppress pepsin, prevents semaglutide from clumping into inactive oligomers, and temporarily fluidizes gastric cell membranes so the drug can cross. The [EMA's public assessment report](https://www.ema.europa.eu/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf) puts the resulting bioavailability at roughly 0.4 to 1%. The [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf) confirms: the vast majority of each dose is destroyed. If you need 280x more API per equivalent dose, your manufacturing cost structure looks nothing like the injectable. A [Yale/King's College study published in JAMA](https://www.fastcompany.com/91071415/your-1000-per-month-ozempic-costs-5-to-make-says-study) found injectable semaglutide costs $0.89 to $4.73 per month to manufacture at the API level. Scale that by 280x and you get oral API costs somewhere in the range of $770 to $1,460 per year, according to [The Medicine Maker's January 2026 analysis](https://themedicinemaker.com/issues/2026/articles/january/oral-glp-1s-won-t-win-on-convenience-they-ll-win-on-cmc/). Still below the selling price. But the margin compression is real, and SNAC itself is a costly excipient. ![Oral semaglutide bioavailability trap: 280x more API per dose than injectable Wegovy, SNAC achieves only 1% absorption, while Eli Lilly Foundayo bypasses the peptide oral delivery problem](https://static.philippdubach.com/cdn-cgi/image/width=1600,quality=85,format=auto/oral-bioavailability-trap.png) SNAC is also oddly specific. [Geiger notes](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) that Novo tried it with liraglutide, a closely related GLP-1 analog, and it failed because liraglutide forms oligomers that SNAC can't break apart. After over three decades of work, exactly two FDA-approved oral peptide drugs using permeation enhancers exist: Rybelsus/oral Wegovy (SNAC) and Mycapssa (oral octreotide for acromegaly, a different enhancer called TPE). ## Foundayo: Lilly's structural advantage Eli Lilly's [orforglipron](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head), approved by the FDA on April 1, 2026 under the brand name [Foundayo](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill), is not an oral peptide. It's a non-peptide small molecule GLP-1 receptor agonist that activates the same receptor through a different mechanism. Discovered by Chugai Pharmaceutical and licensed by Lilly in 2018, orforglipron requires no SNAC, no fasting window, no cold chain storage, and is manufactured through standard chemical synthesis rather than solid-phase peptide synthesis. The bioavailability problem doesn't apply because the molecule was designed from the ground up to survive the gut. In [ACHIEVE-3](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head) (1,698 patients with type 2 diabetes, 52 weeks), orforglipron at 12mg and 36mg was superior to oral semaglutide on both HbA1c reduction and weight loss: the first head-to-head victory over Novo's oral product. In [ATTAIN-2](https://www.appliedclinicaltrialsonline.com/view/eli-lilly-oral-glp1-orforglipron-efficacy-safety-injectable-phaseiii-trial) (obesity with type 2 diabetes), orforglipron delivered 10.5% weight loss at 72 weeks versus 2.2% on placebo. And in [ATTAIN-MAINTAIN](https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after), patients who switched from injectable Wegovy or Mounjaro to oral orforglipron maintained their weight within 0.9 kg over 52 weeks. *Related: [Novo Nordisk's Post-Patent Strategy](https://philippdubach.com/posts/novo-nordisks-post-patent-strategy/)* Lilly [submitted the NDA](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial) with a priority review voucher and received [FDA approval on April 1, 2026](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill), the fastest approval of a new molecular entity since 2002. Foundayo is available starting at $149 per month for self-pay patients, with savings card prices as low as $25 per month. The company is investing [$6.5 billion in a dedicated oral manufacturing facility](https://cen.acs.org/pharmaceuticals/pharmaceutical-chemicals/Lilly-pour-65-billion-GLP/103/web/2025/09) and $27 billion total in US manufacturing capacity. ![Foundayo orforglipron vs oral Wegovy semaglutide comparison: peptide plus SNAC approach versus small molecule across bioavailability, manufacturing cost, fasting requirements, and ACHIEVE-3 clinical results](https://static.philippdubach.com/cdn-cgi/image/width=1600,quality=85,format=auto/peptide-vs-small-molecule.png) ## $70 billion duopoly and its widening crack The gap is widening. Combined GLP-1 revenue from Novo and Lilly hit roughly $70 billion in 2025. But the composition shifted. Lilly's tirzepatide franchise (Mounjaro plus Zepbound) [generated $36.5 billion](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026), with Zepbound alone growing 175% year-over-year. Novo's semaglutide franchise came in around $33 billion, with growth decelerating to roughly 10% in constant exchange rates. [Lilly's US market share hit 57%](https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html) by mid-2025, up from 41% a year earlier. Novo's share fell to 43%. The stock market has been ruthless in pricing this shift. Novo trades at roughly $48 per ADR share, down 65% from its June 2024 peak of $142, a loss exceeding $350 billion in market cap. The company [guided for a 5 to 13% revenue decline in 2026](https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html), driven by patent expirations in Canada, Brazil, and China, plus pricing pressure from the Trump administration's drug pricing framework. CagriSema, Novo's most important pipeline asset, [disappointed twice](https://www.biopharmadive.com/news/novo-nordisk-cagrisema-obesity-drug-study-results/735854/): 22.7% weight loss in REDEFINE 1 (below the company's own 25% guidance) and 15.7% in REDEFINE 2. [Novo's stock plunged 20% on the first readout alone](https://www.cnbc.com/2024/12/20/novo-nordisk-shares-plunge-22percent-after-cagrisema-obesity-drug-trial-results.html). Lilly, by contrast, [guided 2026 revenue at $80 to $83 billion](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026), a 25% increase, and [trades near $1,044](https://finance.yahoo.com/quote/LLY/) with a market cap around $1 trillion, the first pharma company to reach that level. Forward P/E: roughly 30x versus Novo's 12.5x. That 2.4x valuation premium reflects a simple thesis: Lilly has the better drug (Zepbound [showed 47% greater weight loss](https://www.nejm.org/doi/full/10.1056/NEJMoa2416394) than Wegovy in the SURMOUNT-5 head-to-head), the better oral pipeline, and the longer patent runway (tirzepatide patents extend into the mid-2030s versus [semaglutide's core US patent expiring December 2031](https://www.trademarkia.com/news/patents/when-does-the-ozempic-patent-expire), with biosimilar competition likely following shortly after). ![Novo Nordisk vs Eli Lilly GLP-1 duopoly: Lilly at 2.4x Novo forward PE, 57% US market share, revenue and patent runway comparison](https://static.philippdubach.com/cdn-cgi/image/width=1600,quality=85,format=auto/novo-vs-lilly-duopoly.png) The Hims & Hers saga sits at the chaotic edge of all this. HIMS [launched a $49 per month compounded oral semaglutide pill](https://finance.yahoo.com/news/nvo-lly-stocks-slide-hims-142700745.html) on February 5, 2026, using a liposomal formulation for which limited public bioavailability data has been released. Within four days, [HHS had referred the company to the DOJ](https://markets.financialcontent.com/stocks/article/marketminute-2026-2-9-the-glp-1-gold-rush-hits-a-wall-novo-nordisk-sues-hims-and-hers-as-fda-crackdown-triggers-20-stock-crash), Novo had [filed a patent infringement lawsuit](https://www.gurufocus.com/news/8587678/novo-nordisk-nvo-shares-plunge-amid-competition-from-hims-hers-hims), and HIMS had suspended the product. Novo Nordisk has alleged, in filings related to its litigation, elevated impurity levels in compounded samples โ€” the underlying allegation is contested and the case is unresolved, and the figure should not be read as established fact. The episode illustrates what happens when the incentive to undercut $1,000-per-month pricing collides with the engineering difficulty of making peptide drugs work orally. *Related: [Novo Was Europe's Most Valuable Company](https://philippdubach.com/posts/novo-was-europes-most-valuable-company/)* ## Does Oral Delivery Commoditize GLP-1 Oral delivery could commoditize GLP-1s or expand the market enough that the opportunity grows despite pricing pressure. Early evidence supports the expansion thesis: [Novo's oral Wegovy pill uptake is running roughly 10x higher](https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html) than the original injectable Wegovy launch, drawing in new patients rather than converting existing injection users. The statin precedent is the strongest data point we have. After generic atorvastatin launched in 2011, total statin use [expanded from 31 million to 92 million Americans](https://pmc.ncbi.nlm.nih.gov/articles/PMC10203693/) by 2019, a **197% increase**. Total prescription volume grew 77%. The per-unit price collapsed, but total market volume more than compensated. Updated clinical guidelines, lower copays, and reduced patient resistance combined to pull in millions of people who would never have started therapy at the original price and delivery format. Current penetration is absurdly low: [fewer than 5% of eligible US adults](https://icer.org/wp-content/uploads/2025/04/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09.2025.pdf) are on anti-obesity medication therapy, against 104 million with obesity. At statin-like penetration rates of 35% or higher, that's a 5 to 10x expansion. Persistence data reinforces the point: only [32% of obesity patients persist at one year and 15% at two years](https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence). Side effects account for 43.7% of discontinuation, financial barriers for 30.9%. Adherence collapses when the friction is high. An oral weight loss pill that's cheaper, eliminates the injection barrier, and has no fasting restrictions (orforglipron) attacks all three. *Related: [Ozempic is Reshaping the Fast Food Industry](https://philippdubach.com/posts/ozempic-is-reshaping-the-fast-food-industry/)* ## Oral GLP-1 pipeline The rest of the oral GLP-1 pipeline is worth tracking but the outcomes are uncertain. [Viking's oral VK2735](https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-top-line-results-from-phase-2-venture-oral-dosing-trial-of-vk2735-tablet-formulation-in-patients-with-obesity-302533355.html) showed rapid weight loss in Phase 2 (up to 12.2% at 13 weeks) but a [38% discontinuation rate](https://www.biopharmadive.com/news/viking-oral-obesity-drug-results-study-discontinuationsdata-dropout/758019/) at the highest dose sent the stock down 37%. [Structure Therapeutics' aleniglipron](https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access) posted 15.3% placebo-adjusted weight loss at 36 weeks in Phase 2b, competitive numbers with no plateau, and has $786 million in cash to fund Phase 3. [Pfizer's danuglipron was killed](https://www.statnews.com/2025/04/14/pfizer-discontinue-danuglipron-glp-1-obesity-liver-toxicity/) by liver toxicity in April 2025, the second Pfizer oral GLP-1 failure. [Terns Pharmaceuticals also exited](https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2) after weak Phase 2 data and liver enzyme elevations. Behind them, Novo's oral amycretin, a GLP-1/amylin dual agonist, enters Phase 3 in 2026 and could offer best-in-class weight loss if the oral formulation holds up. Oral small molecule GLP-1 development has a meaningful failure rate, and Foundayo's clean safety profile across multiple Phase 3 trials is not something I'd assume the next entrant can replicate. ![Oral GLP-1 pipeline 2026: Foundayo approved, aleniglipron Phase 3, VK2735 Phase 2, oral amycretin Phase 3, with Pfizer and Terns programs killed by liver toxicity](https://static.philippdubach.com/cdn-cgi/image/width=1600,quality=85,format=auto/oral-glp1-pipeline.png) Almost every variable in this market is changing at the same time: form factor (injection to pill), pricing structure ($1,000 per month to $149 and potentially lower), patent protection (expiring internationally, holding domestically), competitive dynamics (Novo growth decelerating per its own guidance, Lilly's Foundayo launching, the compounding-pharmacy retreat after the Hims episode), and the macro question of Medicare coverage. The structural thesis โ€” that oral GLP-1s expand total market volume through a Jevons-like dynamic โ€” is more confident than any view on individual stock entry points. At roughly 30x forward earnings for Lilly and 12.5x for Novo per recent multiples, the market is pricing in very different forward trajectories for the two companies. Which framing turns out to be right depends on what the head-to-head readouts and the orforglipron launch curve actually show in 2026 and 2027. > **Disclaimer.** Journalism, not investment advice or a recommendation. Not directed at UK persons; not a financial promotion under FSMA s.21. The author may hold positions in instruments discussed and receives no compensation from issuers. [Full disclaimer](/disclaimers/#finance). > **Disclaimer.** Journalistic reportage on prescription-only medicines. Not advertising under HMG / HMR / HWG / FDA frameworks, not medical advice. Prescription and use require a qualified clinician. [Full disclaimer](/disclaimers/#pom). --- ## Frequently Asked Questions ### How does oral semaglutide work if absorption is reported at around 1%? Per the EMA assessment report, only 0.4 to 1% of oral semaglutide reaches the bloodstream. The permeation enhancer SNAC (salcaprozate sodium) buffers stomach acid and fluidizes gastric cell membranes, allowing a small fraction of the peptide to cross. The oral 25mg daily dose accordingly uses substantially more active ingredient than the equivalent weekly injection. ### How did Foundayo perform versus oral semaglutide in head-to-head trials? Per Lilly's reported ACHIEVE-3 readout, Foundayo (orforglipron) showed superior results on HbA1c reduction and weight loss versus oral semaglutide 7mg and 14mg doses at 52 weeks. ACHIEVE-3 compared against the diabetes doses, not the higher 25mg Wegovy pill dose approved for obesity, so cross-trial inferences for the obesity indication should be treated cautiously. ### What is the current GLP-1 market size? Combined Novo Nordisk and Eli Lilly GLP-1 revenue reached approximately $70 billion in 2025. Per the companies' Q4 2025 disclosures, Lilly's tirzepatide franchise (Mounjaro + Zepbound) generated $36.5 billion and Novo's semaglutide franchise generated roughly $33 billion. Lilly's US market share was reported at 57% as of mid-2025. ### Will oral GLP-1 pills expand the obesity market or replace injections? Early data favors expansion over cannibalisation. The statin precedent is instructive: after generic atorvastatin launched in 2011, total statin use expanded from 31 million to 92 million Americans by 2019, a 197% increase. Current GLP-1 penetration is under 5% of eligible US adults versus 35%+ for statins, leaving meaningful room as oral delivery reduces friction. ### When does semaglutide's patent expire? Semaglutide's core US patent expires December 5, 2031, with formulation patents extending to 2033. International patents in Canada, China, India, and Brazil are expiring in 2026, opening the door to generic and biosimilar competition outside the US. Tirzepatide patents extend into the mid-2030s. ### What oral GLP-1 weight loss pills are FDA approved in 2026? Two oral GLP-1 pills are FDA approved for weight loss: Novo Nordisk's oral Wegovy pill (semaglutide 25mg), approved December 2025 and launched January 2026, and Eli Lilly's Foundayo (orforglipron), approved April 1, 2026. Behind them, Novo's oral amycretin enters Phase 3 in 2026, Structure Therapeutics' aleniglipron targets mid-2026 Phase 3 start, and Viking Therapeutics' VK2735 oral showed Phase 2 data with elevated discontinuation rates at the highest dose. ### How much does Foundayo cost per month? Per Lilly's disclosure, Foundayo starts at $149 per month for the lowest dose for self-pay patients. Eligible commercially insured patients may pay as little as $25 per month with the savings card. Eligible Medicare Part D individuals may be able to get Foundayo for $50 per month beginning July 2026. The oral Wegovy pill is priced at $149 to $299 per month depending on dose. --- Canonical: https://philippdubach.com/posts/why-lillys-weight-loss-pill-isnt-a-peptide/ This file is the canonical machine-readable variant of https://philippdubach.com/posts/why-lillys-weight-loss-pill-isnt-a-peptide/. Author: Philipp D. Dubach (https://philippdubach.com/).